Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.,The Lancet

当前位置： X-MOL 学术 › Lancet › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
The Lancet ( IF 98.4 ) Pub Date : 2018-01-01 , DOI: 10.1016/s1470-2045(17)30909-9
Jeffrey A Jones ₁ , Anthony R Mato ₂ , William G Wierda ₃ , Matthew S Davids ₄ , Michael Choi ₅ , Bruce D Cheson ₆ , Richard R Furman ₇ , Nicole Lamanna ₈ , Paul M Barr ₉ , Lang Zhou ₁₀ , Brenda Chyla ₁₀ , Ahmed Hamed Salem ₁₁ , Maria Verdugo ₁₀ , Rod A Humerickhouse ₁₀ , Jalaja Potluri ₁₀ , Steven Coutre ₁₂ , Jennifer Woyach ₁ , John C Byrd ₁₃

Affiliation

The Ohio State University, Columbus, OH, USA.
Center for Chronic Lymphocytic Leukemia, University of Pennsylvania, Philadelphia, PA, USA.
University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dana-Farber Cancer Institute, Boston, MA, USA.
UC San Diego Moores Cancer Center, San Diego, CA, USA.
Georgetown University Hospital, Washington, DC, USA.
Weill Cornell Medicine, New York, NY, USA.
Columbia University Medical Center, New York, NY, USA.
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
AbbVie, North Chicago, IL, USA.
AbbVie, North Chicago, IL, USA; Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA, USA.
Division of Pharmaceutics, College of Pharmacy, Columbus, OH, USA.

Therapy targeting Bruton's tyrosine kinase (BTK) with ibrutinib has transformed the treatment of chronic lymphocytic leukaemia. However, patients who are refractory to or relapse after ibrutinib therapy have poor outcomes. Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory chronic lymphocytic leukaemia. In this study, we assessed the activity and safety of venetoclax in patients with chronic lymphocytic leukaemia who are refractory to or relapse during or after ibrutinib therapy.

中文翻译：

Venetoclax 治疗依鲁替尼治疗后进展的慢性淋巴细胞白血病：多中心、开放标签、2 期试验的中期分析。

使用依鲁替尼靶向布鲁顿酪氨酸激酶 (BTK) 的疗法已经改变了慢性淋巴细胞白血病的治疗。然而，对依鲁替尼治疗无效或复发的患者预后较差。 Venetoclax 是一种选择性、口服生物可利用的 BCL-2 抑制剂，对既往治疗过的复发性或难治性慢性淋巴细胞白血病患者有效。在这项研究中，我们评估了维奈托克对伊布替尼治疗期间或治疗后难治或复发的慢性淋巴细胞白血病患者的活性和安全性。

更新日期：2017-12-31

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文